Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Coinbase Global, Inc. (COIN) Price & Performance

Amphastar Pharmaceuticals IncTrade
Coinbase Global, Inc.Trade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Coinbase Global, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Coinbase Global, Inc. trades at $148.69 (market cap $39.23B). The key difference: Coinbase Global, Inc. is far larger — about 45.4× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.

AMPHCOIN
Market Cap
$863.95M$39.23B
Sector
HealthTechnology
52-Week High
$30.81$387.27
52-Week Low
$16.87$141.09
Enterprise Value
$1.26B$36.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Coinbase Global, Inc.

COIN trades at $153.6, up 5.63% in the past 24 hours, but technical indicators signal a bearish trend with resistance near $157. The company reported Q2 2026 revenue of $1.22 billion, missing estimates, and a net loss of $359.5 million, though adjusted EBITDA remained positive for the 14th consecutive quarter. Analyst consensus is a Buy with a $207.20 price target, but recent news highlights crypto market weakness and a Zacks Strong Sell rating on August 6, 2026.

The outlook is mixed: strong cash flow and market share growth offer upside, but consecutive earnings misses and high valuation ratios pose risks. Investors face volatility from crypto market dependence and competitive pressures, requiring caution despite Wall Street's bullish average target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Coinbase Global, Inc.

Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.

Read more on COIN